Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Quarterlies to dictate price moves, as Nanosonics and Neuren come into play
Health & Biotech
The surge and plunge in ASX biotech shows what the FDA giveth, the FDA taketh away
News
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study
Health & Biotech
These 3 ASX health stocks just took their next steps towards entering the USA
Health & Biotech
These ASX biotechs are on the verge of releasing Phase III clinical trial results
Experts
ScoPo’s powerplays: It’s been a rollercoaster ride, but take a look at Neuren
Health & Biotech
Dr Boreham’s Crucible: Is Neuren Pharmaceuticals’ Rett bet set for collect?
Health & Biotech
Orphan Drug Designation: Here’s why it’s a big deal for small cap biotechs
Experts
ScoPo’s powerplays: Searching for gems as healthcare sector languishes
Health & Biotech
Healthkick Podcast: Neuren is cashed up, confident and charging into a phase 3 trial
Experts
ScoPo’s powerplays: ‘It’s a new dawn… get in front of these extraordinary opportunities’
Health & Biotech
Antisense Therapeutics’ FDA ruling could be worth ‘hundreds of millions’
Health & Biotech
World-renown cancer institute to investigate Kazia Therapeutics drug
Health & Biotech
Incannex persists with CBD, hydroxychloroquine COVID drug
Health & Biotech
Health: Immutep has dosed the last patient in one of its cancer studies
News
Rise and Shine: What you need to know before the ASX opens
News
